Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062816 · ClinicalTrials.gov registry record · Phase 1
Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs
A Phase 1 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00062816 is a Phase 1 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 22 participants.
The verdict
NCT00062816, a Phase 1 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purposes of this Phase 1/2 study are to examine the safety, tolerability, and antiviral activity of ISIS 14803, when given in combination with peginterferon alfa and ribavirin, to patients who either failed to have at least a 100-fold HCV reduction at Week 12 of standard therapy or still have detectable HCV at Week 24.
Interventions
- DRUG ISIS 14803, peginterferon alfa, ribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2003-06 |
| Est. Completion | 2004-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062816
The ClinicalTrials.gov registry entry for NCT00062816 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ISIS 14803, peginterferon alfa, ribavirin is the first listed.
NCT00062816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00062816 about?
NCT00062816 is a clinical study titled "Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs". The purposes of this Phase 1/2 study are to examine the safety, tolerability, and antiviral activity of ISIS 14803, when given in combination with peginterferon alfa and ribavirin, to patients who either failed to have at least a 100-fold HCV reduction at Week 12 of standard therapy or still have de...
What is the current status of trial NCT00062816?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2003-06. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00062816?
The interventions under investigation include: ISIS 14803, peginterferon alfa, ribavirin (DRUG).
Who is sponsoring clinical trial NCT00062816?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.